The US patent expirations are expected to be nearly $115-125 billion between CY2023 and CY2026. Of this, biosimilars will comprise around $ 35-40 billion. This is expected to boost the growth of Indian pharma companies over the next few years. Moreover, increasing per capita wallet share of speciality drugs and industry players’ focus on the same is expected to augur well going forward.
